Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Clinical trial NCT03867097 · COMPLETED

Trial details

NCT number: NCT03867097
Sponsor: Civi Biopharma, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Raynaud Phenomenon Secondary to Systemic Sclerosis

Start date: 2019-03-07
Primary completion: 2019-08-06
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.